Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Floor J. Backes"'
Autor:
Elena Ratner, Alessandro D. Santin, Laura J. Havrilesky, Osama Abdelghany, Amanda N. Fader, Angeles Alvarez Secord, Dan-Arin Silasi, Eric R. Siegel, Stefania Bellone, David M. O'Malley, K. ElSahwi, Babak Edraki, Pei Hui, Dana M. Roque, Masoud Azodi, Dirk Pikaart, Natalia Buza, Babak Litkouhi, Setsuko K. Chambers, Paul Celano, Nicole S. Nevadunsky, Floor J. Backes, William J. Lowery, Peter E. Schwartz
Publikováno v:
Clin Cancer Res
Purpose: Uterine-serous-carcinoma (USC) is an aggressive variant of endometrial cancer. On the basis of preliminary results of a multicenter, randomized phase II trial, trastuzumab (T), a humanized-mAb targeting Her2/Neu, in combination with carbopla
Autor:
David E. Cohn, Qi-En Wang, Vincent Wagner, Marissa Werner, Floor J. Backes, Corinne Calo, G. Larry Maxwell, S. Karuppaiyah, Kalpana Deepa Priya Dorayappan
Publikováno v:
Gynecologic Oncology. 162:S173
Objectives: To identify the molecular mechanisms of TMEM205-mediated exosome secretion that leads to the development of chemoresistance in ovarian cancer and determine if targeted inhibition of TMEM205 with small molecule inhibitors can sensitize ova
Autor:
Kristina W. Thiel, Virginia L. Filiaci, Megan I. Samuelson, Gini F. Fleming, Eric J. Devor, Yuping Zhang, Megan E McDonald, Henry D. Reyes, Saketh R. Guntupalli, Parviz Hanjani, Krishnansu S. Tewari, Nilsa C. Ramirez, Floor J. Backes, Kimberly K. Leslie, Jeffrey C. Miecznikowski, Jesus Gonzalez-Bosquet, Jean-Marie Stephan, Michael J. Birrer
Publikováno v:
Reyes, HD; Miecznikowski, J; Gonzalez-Bosquet, J; Devor, EJ; Zhang, Y; Thiel, KW; et al.(2017). High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. GYNECOLOGIC ONCOLOGY, 146(2), 247-253. doi: 10.1016/j.ygyno.2017.05.017. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/5hp2v0d7
Objective Gynecologic Oncology Group (GOG) 177 demonstrated that addition of paclitaxel to a backbone of adriamycin/cisplatin improves overall survival (OS) and progression-free survival (PFS) for patients with advanced or recurrent endometrial cance
Autor:
Eric L. Eisenhauer, Kay J. Park, Floor J. Backes, Dennis S. Chi, Ginger J. Gardner, Destin Black, Mario M. Leitao, Nadeem R. Abu-Rustum, Robert A. Soslow, Renee A. Cowan, Lien N. Hoang
Publikováno v:
Gynecologic Oncology. 142:139-143
Objective The objective of this prospective pilot study was to assess the clinical and histologic effects of topical imiquimod therapy on recurrent extramammary Paget's disease of the vulva. Methods Patients with biopsy-proven recurrent extramammary
Autor:
Floor J. Backes, Ritu Salani, A. Crim, David M. O'Malley, Quan Li, Sarah M. Crafton, David E. Cohn, Caroline C. Billingsley, Erinn M. Hade, Samuel N. Jacobson, Jeffrey M. Fowler, Larry J. Copeland
Publikováno v:
International Journal of Gynecologic Cancer. 25:1331-1336
ObjectiveWe assessed the safety and efficacy of administration of pegfilgrastim on the same day compared with standard administration 24 to 72 hours after chemotherapy in patients with gynecologic malignancies.MethodsA retrospective review was conduc
Autor:
Babak Litkouhi, Masoud Azodi, Dirk Pikaart, Alessandro D. Santin, Paul Celano, Eric R. Siegel, Natalia Buza, Babak Edraki, K. ElSahwi, Amanda N. Fader, Osama Abdelghany, Elena Ratner, Angeles Alvarez Secord, Peter E. Schwartz, Nicole S. Nevadunsky, Stefania Bellone, Dana M. Roque, Setsuko K. Chambers, Laura J. Havrilesky, Floor J. Backes, William J. Lowery, Dan-Arin Silasi, Pei Hui, David M. O'Malley
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 36(20)
Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, a receptor overexpressed in 30% of uterine serous c
Autor:
Mark F. Brady, Barbara M. Norquist, Robert S. Mannel, Heather A. Lankes, Krishnansu S. Tewari, Cheryl Bailey, Nilsa C. Ramirez, Michael J. Birrer, Robert A. Burger, Elizabeth M. Swisher, Suleyman Gulsuner, Ming K. Lee, Stephen C. Rubin, Mary Claire King, Tom Walsh, Silvia Casadei, Gretchen E. Glaser, Floor J. Backes, Sarah S. Bernards, John T. Soper, Maria I. Harrell
Purpose: We hypothesized that mutations in homologous recombination repair (HRR) genes beyond BRCA1 and BRCA2 improve outcomes for ovarian carcinoma patients treated with platinum therapy and would impact the relative benefit of adding prolonged beva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4592a7c44d3260a642407fb3f1247dc
https://europepmc.org/articles/PMC5815909/
https://europepmc.org/articles/PMC5815909/
Autor:
David E. Cohn, Quan Li, Ritu Salani, Allyson Waller, David M. O'Malley, Floor J. Backes, Jeffrey M. Fowler, Larry J. Copeland
Publikováno v:
Gynecologic Oncology. 135:90-94
Objective The primary objective of this study is to assess the efficacy and safety of an outpatient, 4-step, one-solution desensitization protocol in gynecologic oncology patients with history of mild to low-risk, moderate hypersensitivity reactions
Autor:
Blair Smith, David M. O'Malley, Jeffrey M. Fowler, Debra L. Richardson, David E. Cohn, Floor J. Backes, Georgia A. McCann, Ritu Salani, Larry J. Copeland, Eric L. Eisenhauer
Publikováno v:
International Journal of Gynecologic Cancer. 23:833-838
ObjectiveThe optimal role of bevacizumab (Bev) in the treatment of ovarian cancer has not yet been established. Furthermore, it is unclear whether there is a benefit of Bev after progression on a Bev-containing regimen in ovarian cancer. The objectiv
Autor:
Debra L. Richardson, Leigh G. Seamon, Floor J. Backes, Larry J. Copeland, David M. O'Malley, Vanna Zanagnolo, David E. Cohn, Jeffrey M. Fowler
Publikováno v:
Gynecologic Oncology. 111:461-466
Objective To describe the response rate (RR), progression-free survival (PFS), and toxicity profile of combination gemcitabine, platinum, and bevacizumab (GPB) for the treatment of recurrent epithelial ovarian cancer (EOC). Methods A chart review of